BVSC + Clinical Trials
BVSC fosters creativity and ethical collaborative research that allows us to challenge and discover new treatment options to improve quality of life.
BVSC + specialty care with compassion
Home of the Australian Animal Cancer Foundation

+ Tigilanol Tiglate Mast Cell Tumour Trial

Mast cell tumours are common in dogs and represent the most common malignant skin tumour in this species.  They have a wide variation in presentation, biological behaviour and response to therapy.  There is not one single way to effectively treat all mast cell tumours in dogs.  We are evaluating a novel, intratumoural injection which may be very useful to manage this disease in certain cases.  Our oncology specialist team can advise the suitability or otherwise of this product, in cases of canine mast cell tumour and if there is suitability to participate in our trial.  Please contact Dr Rod Straw and Julia Cathie info@bvsc.com.au or call 07 3264 9400

 _______________________________________________________________________________________________________________________________________________

BVSCPET CT OsteoStudyHeader

An Australian company, QBiotics Group Limited, has developed an intratumoural treatment for mast cell tumours (MCTs) in dogs.  This drug has been approved by the European Medicine Agency, SwissMed, UK Veterinary Medicines Directorate and the US Food and Drug Administration’s Centre for Veterinary Medicine and is marketed in Europe, UK and the USA as Stelfonta.  The active ingredient is Tigilanol tiglate (TT) which is a novel small molecule pharmaceutical for use in non-metastatic cutaneous MCTs and subcutaneous MCTs located at or below the elbow and hock. Although, the drug is derived from a seed found in North Queensland rainforests, it is not licenced for use in Australia.  A regulatory submission for use of the drug is currently under consideration by the APVMA.

Approval has been given for a trial of TT in dogs in Australia and Brisbane Veterinary Specialist Centre, home of the Australian Animal Cancer Foundation, is one of the approved sites. The study will provide further efficacy and safety data as well as pave the way for safe and appropriate use of this drug when it becomes available to Australian veterinarians. The study involves up to 40 dogs Australia-wide with the estimated last recruitment in July 2021.

The inclusion criteria are relatively healthy dogs over one year of age with a cytological diagnosis of one or more cutaneous or subcutaneous (below the elbow and/or hock) mast cell tumours without evidence of metastasis.   

If you believe you may have a case that meets these criteria,  please contact Julia Cathie or Rod Straw at BVSC on 07 3264 9400

BVSC Clinical Trials - Tigilanol Tiglate Mast Cell Tumour Trial